Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain
Cancer
Explore 1,380 assets in Cancer →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Institut Bergonié
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05888857CT.gov MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT05685472CT.gov MEDI5752 in Japanese Patients With Advanced Solid Tumors. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain (this asset) | Institut Bergonié | P2 | CCC · 50 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 43 |
| Neoplasm | — | P1 | CC · 43 |
| Renal Cell Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 (134-Cysteine,228-Valine,242-Phenylalanine,243-Glutamic Acid,339-Serine,362-Cysteine,374-Tryptophan), Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Medi5752 .Gamma.1-Chain), Disulfide With (122-Cysteine,212-Valine) Human Monoclonal Medi5752 .Lambda.-Chain, (234->231')(237->234')(362->354') Tris(Disulfide) With Immunoglobulin G1 (239-Phenylalanine,240-Glutamic Acid,336-Serine,354-Cysteine,371-Serine,373-Alanine,412-Valine) Anti-(Human Programmed Cell Death Protein 1) (Human-Mus Musculus Monoclonal Medi5752 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Medi5752 .Kappa.-Chain in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-134-cysteine228-valine242-phenylalanine243-glutamic-acid339-serine362-cysteine374-tryptophan-anti-human-cytotoxic-t-lymphocyte-associated-protein-4-human-monoclonal-medi5752-gamma1-chain-disulfide-with-122-cysteine212-valine-human-monoclonal-medi5752-lambda-chain-234-231237-234362-354-trisdisulfide-with-immunoglobulin-g1-239-phenylalanine240-glutamic-acid336-serine354-cysteine371-serine373-alanine412-valine-anti-human-programmed-cell-death-protein-1-human-mus-musculus-monoclonal-medi5752-gamma1-chain-disulfide-with-human-mus-musculus-monoclonal-medi5752-kappa-chain-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →